Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: A Portuguese hospital study

Hemoglobin

Volumn 29, Issue 3, 2005, Pages 171-180

  Braga, Lígia Barbosa ^a   Ferreira, Ana Cristina ^a   Guimarães, Margarida ^a   Nazário, Carlos ^a   Pacheco, Paula ^b   Miranda, Armandina ^b   Picanço, Isabel ^b   Seixas, Teresa ^b   Rosado, Lino ^a   Videira Amaral, João M ^a  

^a HOSPITAL DONA ESTEFÂNIA   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Children; Hydroxyurea (HU); Sickle cell anemia

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LABORATORY DIAGNOSIS; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PATIENT COMPLIANCE; POPULATION RISK; PORTUGAL; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; FEMALE; FETAL HEMOGLOBIN; HOSPITALS; HUMANS; HYDROXYUREA; LABORATORIES, HOSPITAL; MALE; PORTUGAL; PROSPECTIVE STUDIES;

EID: 23244435020     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1081/HEM-200066299     Document Type: Article

References (28)

1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910; 6:517-521.
2. Watson J, Stahman AW, Bilello FP. The significance of the paucity of sickled cells in newborn Negro infants. Am J Med Sci 1948; 215:419-423.
3. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332(20):1317-1322.
4. Ferster A, Vermylen C, Comu G, Buyse M, Corazza F, Devalck C, Fondu P, Toppet M, Sariban E. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88(6):1960-1964.
5. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94(5): 1550-1554.
6. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E. Five years experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97(11):3628-3632.
7. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment Hematology (Am Soc Hematol Educ Program) 2000:2-17.
8. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111(2):231-239.
9. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89(7):2554-2559.
10. Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J 2000; 1(5):295-300.
11. Ohene-Frempong K, Horiuchi K, Bulgarelli W. Hydroxyurea increases Hb F production in children with sickle cell disease. Blood 1993; 82:472a (abstract).
12. Oury AP, Hoyoux C, Dresse MF, Chantraine JM. Sickle cell anemia in children: value of hydroxyurea in severe forms. Arch Pediatr 1997; 4(9):839-844.
13. de Montalembert M, Begue P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child 1999; 81(5):437-439.
14. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128(6):820-828.
15. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol/Oncol 1998; 20(1):26-31.
16. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 1997; 34[3 (suppl 3)]:42-47.
17. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996; 129(4):559-565.
18. Ohene-Frempong K, Horiuchi K, Stoeckrlt C. Sustained effect of hydroxyurea on Hb F production in children with sickle cell disease, In: Proceedings of the XX Annual Meeting of the National Sickle Cell Disease Program, Boston, MA, USA, March 18-21, 1995:215, (abstract).
19. Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell β-thalassemia. Pediatr Hematol Oncol 1999; 16(3):221-232.
20. Lamy S, Braga L, Lavinha J, Gomes da Costa G, Cordeiro Ferreira N. Profilaxia das doenças hereditárias do eritrócito. Acta Med Port 1995; 8(6):355-358.
21. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50(2):140-143.
22. Huang Z, Louderback JG, King SB, Ballas SK, Kim-Shapiro DB. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability. Am J Hematol 2001; 67(3):151-156.
23. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol 1990; 27(4):360-376.
24. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988; 318(2):96-99.
25. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330(23):1639-1644.
26. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr, Platt OS. Hydroxyurea: effects on Hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79(10):2555-2565.
27. Davies SC, Beuzard Y, Borgna-Pignatti C. The effect of hydroxyurea in sickle cell disease: a European registry of benefits and toxicity (abstract). Hematology 1999; 84:PO-0980.
28. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996; 88(6):1951-1953.